FDA's oral Relistor approval triggers Progenics milestone

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) gained $1.20 (24%) to $6.14 on Wednesday after it and

Read the full 140 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE